These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9098658)

  • 1. Antifungal agents in the 1990s. Current status and future developments.
    Kauffman CA; Carver PL
    Drugs; 1997 Apr; 53(4):539-49. PubMed ID: 9098658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
    Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
    Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current drug therapy of systemic mycoses: a review.
    Yonga G
    East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
    van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
    N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral azole drugs as systemic antifungal therapy.
    Como JA; Dismukes WE
    N Engl J Med; 1994 Jan; 330(4):263-72. PubMed ID: 8272088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
    Goa KL; Barradell LB
    Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome.
    Zeind CS; Cleveland KO; Menon M; Brown JR; Solomon DK
    Pharmacotherapy; 1996; 16(4):547-61. PubMed ID: 8840361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of candidiasis and cryptococcosis in AIDS].
    Just-Nübling G
    Mycoses; 1994; 37 Suppl 2():56-63. PubMed ID: 7609745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
    Castagnola E; Bucci B; Montinaro E; Viscoli C
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antifungal agents.
    Graybill JR
    Eur J Clin Microbiol Infect Dis; 1989 May; 8(5):402-12. PubMed ID: 2546775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal agents. Part II. The azoles.
    Terrell CL
    Mayo Clin Proc; 1999 Jan; 74(1):78-100. PubMed ID: 9987539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Choice and use of antifungal drugs].
    Dupont B
    Rev Prat; 2001 Apr; 51(7):752-7. PubMed ID: 11387672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of systemic mycoses in immunodeficiency].
    Just-Nübling G; Stille W
    Immun Infekt; 1991 Aug; 19(4):116-20. PubMed ID: 1937558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the treatment of systemic fungal infections.
    Walsh TJ
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of azoles in antifungal therapy.
    Kauffman CA
    Clin Infect Dis; 1996 May; 22 Suppl 2():S148-53. PubMed ID: 8722843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
    Van Cutsem J
    Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.